Patents by Inventor Blake Lash

Blake Lash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250122471
    Abstract: Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.
    Type: Application
    Filed: December 23, 2024
    Publication date: April 17, 2025
    Inventors: Feng Zhang, Blake Lash, Daniel Strebinger
  • Publication number: 20250120915
    Abstract: Described in certain example embodiments herein are engineered delivery vesicle generations systems capable of producing engineered delivery vesicles containing two or more different retroelement polypeptides. Also described herein are methods of making and using the engineered delivery vesicles, such as to deliver one or more cargoes.
    Type: Application
    Filed: December 23, 2024
    Publication date: April 17, 2025
    Inventors: Guilhem Faure, Feng Zhang, Blake Lash, Rumya Raghavan, Victoria Madigan
  • Publication number: 20250073350
    Abstract: Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
    Type: Application
    Filed: January 4, 2023
    Publication date: March 6, 2025
    Inventors: Feng Zhang, Michael Segel, Blake Lash, Daniel Strebinger
  • Patent number: 12195723
    Abstract: Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 14, 2025
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Blake Lash, Daniel Strebinger
  • Publication number: 20240084330
    Abstract: Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more LTR retroelement polypeptides for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more LTR retroelement polypeptides for forming a delivery vesicle may comprise two or more of an LTR retroelement gag protein, a retroelement envelope protein, a an LTR retroelement reverse transcriptase, or a combination thereof. The LTR retroelement polypeptide alone, the LTR retroelement envelope protein alone, or both the LTR retroelement-derived polypeptide and LTR retroelement envelope protein may be endogenous.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 14, 2024
    Inventors: Feng Zhang, Michael Segel, Blake Lash
  • Publication number: 20210147799
    Abstract: Described herein are engineered antigen presenting cells that can be capable of modulating a target T-cell in a T-cell antigen specific manner. In some embodiments, the engineered APCs can include a modified antigen presentation pathway. Also described herein are methods of making and using the engineered antigen presenting cells.
    Type: Application
    Filed: November 9, 2020
    Publication date: May 20, 2021
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Feng Zhang, Blake Lash, Daniel Strebinger